Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Zostavax Shingles Vaccine Safe and Effective For Adults Over 60, Committee Says

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Vaccines & Related Biological Products Advisory Committee said data do not support Merck's proposed indication for adults as young as 50 years.

You may also be interested in...



Zostavax Gets Nod For Younger Age Group, But Supply Issues Make Sales Boost Unlikely

Merck's ability to capitalize on FDA approval of the shingles vaccine in patients ages 50-59 years is questionable given ongoing supply constraints.

Zostavax Gets Nod For Younger Age Group, But Supply Issues Make Sales Boost Unlikely

Merck's ability to capitalize on FDA approval of the shingles vaccine in patients ages 50-59 years is questionable given ongoing supply constraints.

Merck’s Zostavax Shingles Vaccine Approved For Patients Over 60

FDA says Merck would need to present more data to pursue use in patients ages 50-59.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel